Supernus Pharmaceuticals SUPN
$28.61 +$0.26 (+0.92%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $28.00 -2.13%
Open$28.39
Prev close$28.35
Day range$28.15 – $29.51
Volume2.83M
Market cap$5.94B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±2.3%last 16 reports
Closed higher11 of 1669% of the time
Best reaction+6.1%
Worst reaction-5.8%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | After Market | ±12.1% | +0.34% | Within range |
| 2026/Q2 | 4 Aug 2026 | After Market | ±11.6% | +6.11% | Within range |
| 2026/Q1 | 5 May 2026 | After Market | ±12.4% | +2.58% | Within range |
| 2025/Q4 | 24 Feb 2026 | After Market | ±13.5% | +1.72% | Within range |
| 2025/Q3 | 4 Nov 2025 | After Market | ±11.2% | +0.16% | Within range |
| 2025/Q2 | 5 Aug 2025 | After Market | – | +0.92% | – |
| 2025/Q1 | 6 May 2025 | After Market | ±12.3% | -1.88% | Within range |
| 2024/Q4 | 25 Feb 2025 | After Market | ±8.5% | +3.87% | Within range |
| 2024/Q3 | 4 Nov 2024 | After Market | ±10.9% | +0.33% | Within range |
| 2024/Q2 | 6 Aug 2024 | After Market | ±10.7% | -2.22% | Within range |
| 2024/Q1 | 8 May 2024 | After Market | ±11.5% | +0.51% | Within range |
| 2023/Q4 | 27 Feb 2024 | After Market | ±20.2% | -1.57% | Within range |
| 2023/Q3 | 8 Nov 2023 | After Market | ±10.6% | -5.47% | Within range |
| 2023/Q2 | 8 Aug 2023 | After Market | ±6.3% | +1.08% | Within range |
| 2023/Q1 | 9 May 2023 | After Market | ±16.4% | +1.49% | Within range |
| 2022/Q3 | 8 Nov 2022 | None | ±10.2% | -5.82% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$226.77M+18.0% YoY
Operating profit$22.72M+137.7% YoY
Net profit$20.91M+146.4% YoY
Diluted EPS$0.35+143.8% YoY
Free cash flow$6.38M+110.3% YoY
Operating cash flow$6.61M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin87.6%
Operating margin3.2%
Net margin-5.1%
Return on equity-4.2%
Return on assets-3.1%
Return on invested capital-4.3%
Current ratio2.49
Liabilities / assets24.0%
Cash & investments$359.46M
Total debt$28.58M
Net cash (debt)$330.88M
Free cash flow / sales10.1%
No comments yet — be the first to weigh in on SUPN.
Sign in to join the discussion.